TP53 and cancer: It is reasonable to surmise that: (i) the response of the PR-LncRNAs might be different in clinical samples and cell lines and also upon stressful conditions in vitro; (ii) the activity and regulation of the signature might be partially different within the different types of cancer; and (iii) some of the PR-LncRNAs might be regulated in a p53-independent manner, given that only around ~3% of the PR-LncRNAs altered by DNA damage in colorectal cells were directly bound by p5319.